Barclays PLC acquired a new stake in shares of Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB – Free Report) during the third quarter, HoldingsChannel.com reports. The institutional investor acquired 247,575 shares of the company’s stock, valued at approximately $169,000.
Separately, FMR LLC purchased a new stake in Lakeshore Biopharma in the third quarter valued at about $803,000. Institutional investors own 52.64% of the company’s stock.
Lakeshore Biopharma Stock Performance
LSB opened at $3.50 on Wednesday. The firm’s 50-day moving average is $2.79. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.87 and a current ratio of 1.13. Lakeshore Biopharma Co., Ltd. has a 52-week low of $1.88 and a 52-week high of $11.20.
Lakeshore Biopharma Company Profile
LakeShore Biopharma Co, Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
Further Reading
- Five stocks we like better than Lakeshore Biopharma
- Most Volatile Stocks, What Investors Need to Know
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Investing in Construction Stocks
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- How to Plot Fibonacci Price Inflection Levels
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Want to see what other hedge funds are holding LSB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB – Free Report).
Receive News & Ratings for Lakeshore Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakeshore Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
